Refining the treatment of NSCLC according to histological and molecular subtypes (Q38473472)

3 September 2017

1 reference

title

Refining the treatment of NSCLC according to histological and molecular subtypes (English)

1 reference

non-small-cell lung carcinoma

3 September 2017

main subject

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25963091%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Anish Thomas

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25963091%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Stephen V Liu

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25963091%20AND%20SRC:MED&resulttype=core&format=json

Subramaniam Nachimuthu Deepa

11 June 2020

series ordinal

3

object named as

Deepa S Subramaniam

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25963091%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

language of work or name

English

0 references

publication date

12 May 2015

1 reference

Nature Reviews Clinical Oncology

3 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25963091%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25963091%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25963091%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

page(s)

511-526

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25963091%20AND%20SRC:MED&resulttype=core&format=json

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

11 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

31 March 2020

Cancer statistics, 2015

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Alkylating agents in bronchogenic carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Paclitaxel plus carboplatin: an effective combination chemotherapy for advanced non-small-cell lung cancer or just another Elvis sighting?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

The response of various types of bronchogenic carcinoma to nitrogen mustard

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

First-line crizotinib versus chemotherapy in ALK-positive lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Acquired resistance to TKIs in solid tumours: learning from lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

The quest to overcome resistance to EGFR-targeted therapies in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Patient-derived models of acquired resistance can identify effective drug combinations for cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Spatial and temporal diversity in genomic instability processes defines lung cancer evolution

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Ceritinib in ALK-rearranged non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Immunotherapies for non-small-cell lung cancer and mesothelioma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Genetic basis for clinical response to CTLA-4 blockade in melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

New targetable oncogenes in non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

ROS1 rearrangements define a unique molecular class of lung cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Designing transformative clinical trials in the cancer genome era.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Comprehensive genomic characterization of squamous cell lung cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Genome sequencing identifies a basis for everolimus sensitivity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Biomarkers: exceptional responders-discovering predictive biomarkers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Consensus report of a joint NCI thoracic malignancies steering committee: FDA workshop on strategies for integrating biomarkers into clinical development of new therapies for lung cancer leading to the inception of "master protocols" in lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

ERCC1 isoform expression and DNA repair in non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Treating patients with EGFR-sensitizing mutations: first line or second line--is there a difference?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Impact of tumour volume on the potential efficacy of therapeutic vaccines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Targeted therapies to improve tumor immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.90

Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25963091

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25963091

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25963091